PMC:7441788 / 25746-26036 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T284","span":{"begin":221,"end":226},"obj":"Chemical"},{"id":"T285","span":{"begin":269,"end":274},"obj":"Chemical"}],"attributes":[{"id":"A284","pred":"chebi_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A285","pred":"chebi_id","subj":"T285","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"eceived HCQ (1200 mg daily for 3 days, and then 800 mg daily for 2 weeks [mild to moderate disease] or 3 weeks [severe disease]). The results showed that the 28-days negative conversion probability in ‘standard care’＋HCQ group was 85.4%, similar to the ‘standard care’ group (81.2%). HCQ di"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T186","span":{"begin":130,"end":283},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"eceived HCQ (1200 mg daily for 3 days, and then 800 mg daily for 2 weeks [mild to moderate disease] or 3 weeks [severe disease]). The results showed that the 28-days negative conversion probability in ‘standard care’＋HCQ group was 85.4%, similar to the ‘standard care’ group (81.2%). HCQ di"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"914","span":{"begin":8,"end":11},"obj":"Chemical"},{"id":"915","span":{"begin":284,"end":287},"obj":"Chemical"}],"attributes":[{"id":"A914","pred":"pubann:denotes","subj":"914","obj":"MESH:D006886"},{"id":"A915","pred":"pubann:denotes","subj":"915","obj":"MESH:D006886"}],"text":"eceived HCQ (1200 mg daily for 3 days, and then 800 mg daily for 2 weeks [mild to moderate disease] or 3 weeks [severe disease]). The results showed that the 28-days negative conversion probability in ‘standard care’＋HCQ group was 85.4%, similar to the ‘standard care’ group (81.2%). HCQ di"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T126","span":{"begin":91,"end":98},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"},{"id":"T127","span":{"begin":119,"end":126},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"eceived HCQ (1200 mg daily for 3 days, and then 800 mg daily for 2 weeks [mild to moderate disease] or 3 weeks [severe disease]). The results showed that the 28-days negative conversion probability in ‘standard care’＋HCQ group was 85.4%, similar to the ‘standard care’ group (81.2%). HCQ di"}

{"project":"LitCovid-PubTator","denotations":[{"id":"914","span":{"begin":8,"end":11},"obj":"Chemical"},{"id":"915","span":{"begin":284,"end":287},"obj":"Chemical"}],"attributes":[{"id":"A914","pred":"tao:has_database_id","subj":"914","obj":"MESH:D006886"},{"id":"A915","pred":"tao:has_database_id","subj":"915","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"eceived HCQ (1200 mg daily for 3 days, and then 800 mg daily for 2 weeks [mild to moderate disease] or 3 weeks [severe disease]). The results showed that the 28-days negative conversion probability in ‘standard care’＋HCQ group was 85.4%, similar to the ‘standard care’ group (81.2%). HCQ di"}

{"project":"LitCovid-sentences","denotations":[{"id":"T186","span":{"begin":130,"end":283},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"eceived HCQ (1200 mg daily for 3 days, and then 800 mg daily for 2 weeks [mild to moderate disease] or 3 weeks [severe disease]). The results showed that the 28-days negative conversion probability in ‘standard care’＋HCQ group was 85.4%, similar to the ‘standard care’ group (81.2%). HCQ di"}